The first RSV vaccines were approved in the US in May last year. GSK’s Arexvy vaccine generated more than $1bn in sales in ...
Respiratory syncytial virus, or RSV, season is just a few months away, but new vaccine options have already arrived for ...
GlobalData on MSN1d
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase IUK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations ...
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback